Business Context and Reporting Period
This Form 8-K is filed by P3 Health Partners Inc. on May 14, 2026, regarding events occurring through May 15, 2026. The filing addresses the Company's efforts to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity. The Company had previously received a deficiency notice in November 2025 and was granted an extension until May 20, 2026, to submit a compliance plan.
Key Financial Metrics and Transactions
The filing details significant capital structure changes executed to address the equity deficiency:
- Debt Exchange: Approximately $252,479,967 of outstanding promissory notes (including principal, accrued interest, and back-end fees) was exchanged for non-convertible, non-voting preferred stock with a stated value of $100 per share.
- Capital Raise: The Company entered into a Securities Purchase Agreement to issue up to $70.0 million in units consisting of Series D 19.5% Cumulative Preferred Stock and warrants. As of the filing date, $30.0 million of these units had been sold.
- Compliance Status: Management believes these transactions have restored compliance with the $2.5 million stockholders' equity requirement.
The filing references an unaudited pro forma condensed consolidated balance sheet as of March 31, 2026, adjusted for these transactions. Specific revenue, profit, cash flow, or margin figures are not provided in this document; investors are directed to the Form 10-Q filed on the same date for detailed financial statements.
Material Changes Versus Prior Period
The primary material change is the conversion of approximately $252.5 million in debt obligations into equity (preferred stock) and the infusion of $30.0 million in new capital. This contrasts with the prior period where the Company failed to meet the minimum stockholders' equity threshold, risking delisting. The filing does not provide comparative revenue or operating income data for the period.
Outlook, Risks, and Management Commentary
Management asserts that the Company has regained compliance with Nasdaq listing standards as of the filing date. However, the filing notes that Nasdaq will continue to monitor ongoing compliance. If the Company fails to evidence compliance in its next periodic report, it may be subject to delisting. The preferred stock issued in the debt exchange does not have voting or preemptive rights and is not registered or listed.
Investor Verification Checklist
- Verify the unaudited pro forma condensed consolidated balance sheet (Exhibit 99.1) to confirm the $2.5 million stockholders' equity threshold is met.
- Review the Form 10-Q for the quarter ended March 31, 2026, for actual revenue, cash flow, and debt levels prior to the exchange.
- Confirm the terms of the Series D 19.5% Cumulative Preferred Stock and the associated warrants issued to affiliates of Chicago Pacific Founders (CPF).
- Monitor future periodic reports to ensure the Company maintains the required equity levels to avoid delisting.